Why hasn’t Abivax been acquired despite hot biotech M&A activity in 2026?

STAT reported that biotech M&A was unusually strong in September 2026, yet Abivax still had not been bought. The article suggests possible reasons include buyer concerns about price, regulatory or clinical uncertainty, or better near-term uses of capital, indicating acquirers may be applying a meaningful risk discount.